+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Natera Inc (NTRA) - Product Pipeline Analysis, 2021 Update

  • ID: 5367401
  • Company Profile
  • June 2021
  • 45 pages
  • GlobalData

FEATURED COMPANIES

  • Exact Sciences Corp
  • Guardant Health Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Natera Inc (Natera), formerly Gene Security Network LLC, develops cell-free deoxyribonucleic acid (cfDNA) testing solutions. The company’s products include Signatera, a personalized ctDNA (circulating tumor DNA) blood test to assess MRD (molecular residual disease) and its recurrence; Aletra, a tissue based genomic profiling test to identify genomic alterations and oncology biomarkers in a tumor; Prospera, a transplant rejection test to evaluate the risk of rejection of a transplanted kidney. It also offers Renasight test to detect genetic cause of kidney diseases; Horizon carrier screening test; Panorama non-invasive prenatal screening test; Empower hereditary cancer test; Vistara prenatal single gene screening test; Anora miscarriage test; and Spectrum preimplantation genetic test. Natera is headquartered in Austin, Texas, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and helps to create effective counter strategies to gain a competitive advantage.

Scope
  • The report reviews the detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Natera Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides a detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date
Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Exact Sciences Corp
  • Guardant Health Inc
  • MORE
Natera Inc Company Overview
  • Natera Inc Company Snapshot
  • Natera Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Natera Inc - Pipeline Analysis Overview
  • Natera Inc - Key Facts
  • Natera Inc - Major Products and Services
  • Natera Inc Pipeline Products by Development Stage
  • Natera Inc Ongoing Clinical Trials by Trial Status
Natera Inc Pipeline Products Overview
  • Panorama Non-Invasive Prenatal Expanded Test
  • Panorama Non-Invasive Prenatal Expanded Test Product Overview
  • Prospera Kidney Transplant Rejection Test
  • Prospera Kidney Transplant Rejection Test Product Overview
  • Prospera Kidney Transplant Rejection Test Clinical Trial
  • Reproductive Health Test
  • Reproductive Health Test Product Overview
  • Signatera - Bladder Cancer
  • Signatera - Bladder Cancer Product Overview
  • Signatera - Breast Cancer
  • Signatera - Breast Cancer Product Overview
  • Signatera - Breast Cancer Clinical Trial
  • Signatera - GI Tumors
  • Signatera - GI Tumors Product Overview
  • Signatera - Lung Cancer (Opdivo)
  • Signatera - Lung Cancer (Opdivo) Product Overview
  • Signatera - Lung Cancer (Opdivo) Clinical Trial
  • Signatera - Metastatic Non-Small Cell Lung Cancer
  • Signatera - Metastatic Non-Small Cell Lung Cancer Product Overview
  • Signatera - Molecular Residual Disease (MRD) Assay
  • Signatera - Molecular Residual Disease (MRD) Assay Product Overview
  • Signatera - Multiple Myeloma
  • Signatera - Multiple Myeloma Product Overview
  • Signatera - Multiple Myeloma Clinical Trial
  • Signatera - Non-Hodgkin's Lymphoma
  • Signatera - Non-Hodgkin's Lymphoma Product Overview
  • Signatera - Pan-Cancer
  • Signatera - Pan-Cancer Product Overview
  • Signatera - Prostate Cancer
  • Signatera - Prostate Cancer Product Overview
  • Signatera Companion Diagnostic - Tecentriq
  • Signatera Companion Diagnostic - Tecentriq Product Overview
Natera Inc - Key Competitors

Natera Inc - Key Employees

Natera Inc - Locations and Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • Natera Inc, Recent Developments
  • Jun 04, 2021: Natera Announces New Prospera Data at the ATC 2021 Virtual Connect Conference
  • Apr 29, 2021: Natera Announces First Quarter 2021 Earnings Conference Call
  • Feb 23, 2021: Natera to Participate in the Cowen 41st Annual Health Care Conference
  • Jan 20, 2021: Natera files patent infringement suit against Inivata
  • Dec 18, 2020: U.S. patent office upholds validity of Natera's early priority date '592 cfDNA patent
  • Oct 05, 2020: Court rejects ArcherDX's motion to dismiss Natera's patent infringement case
  • Aug 07, 2020: Natera files additional suit against ArcherDX
  • Jun 17, 2020: Anju Software welcomes Natera to its PUBSTRAT partner community
  • May 18, 2020: Natera and Illumina settle patent dispute
  • Apr 15, 2020: Natera asserts three new oncology patents against ArcherDX
Appendix
  • Methodology
  • About the Publisher
List of Tables
  • Natera Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Natera Inc Pipeline Products by Equipment Type
  • Natera Inc Pipeline Products by Indication
  • Natera Inc Ongoing Clinical Trials by Trial Status
  • Natera Inc, Key Facts
  • Natera Inc, Major Products and Services
  • Natera Inc Number of Pipeline Products by Development Stage
  • Natera Inc Pipeline Products Summary by Development Stage
  • Natera Inc Ongoing Clinical Trials by Trial Status
  • Natera Inc Ongoing Clinical Trials Summary
  • Panorama Non-Invasive Prenatal Expanded Test - Product Status
  • Panorama Non-Invasive Prenatal Expanded Test - Product Description
  • Prospera Kidney Transplant Rejection Test - Product Status
  • Prospera Kidney Transplant Rejection Test - Product Description
  • Prospera Kidney Transplant Rejection Test - INTERCOMEX DD-cfDNA-HLA-MMDx Study: Comparing the DD-cfDNA Test to MMDx Microarray Test, Central HLA Antibody Test, and Histology
  • Prospera Kidney Transplant Rejection Test - PEDAL Study: Prospera Test Enhancement by Detecting Background Cell-free DNA Levels
  • Prospera Kidney Transplant Rejection Test - Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
  • Prospera Kidney Transplant Rejection Test - The Prospera Kidney Transplant Active Rejection Assessment Registry: ProActive
  • Reproductive Health Test - Product Status
  • Reproductive Health Test - Product Description
  • Signatera - Bladder Cancer - Product Status
  • Signatera - Bladder Cancer - Product Description
  • Signatera - Breast Cancer - Product Status
  • Signatera - Breast Cancer - Product Description
  • Signatera - Breast Cancer - A Clinical Study To Evaluate the Molecular Response and Minimal Residual Disease (MRD) in Women with Early Stage Breast Cancer
  • Signatera - Breast Cancer - Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
  • Signatera - GI Tumors - Product Status
  • Signatera - GI Tumors - Product Description
  • Signatera - Lung Cancer (Opdivo) - Product Status
  • Signatera - Lung Cancer (Opdivo) - Product Description
  • Signatera - Lung Cancer (Opdivo) - Signatera ctDNA Assay as a Potential Biomarker for Opdivo (Nivolumab) in a Prospective Phase 2 Adjuvant Non-Small Cell Lung Cancer Clinical Trial
  • Signatera - Metastatic Non-Small Cell Lung Cancer - Product Status
  • Signatera - Metastatic Non-Small Cell Lung Cancer - Product Description
  • Signatera - Molecular Residual Disease (MRD) Assay - Product Status
  • Signatera - Molecular Residual Disease (MRD) Assay - Product Description
  • Signatera - Multiple Myeloma - Product Status
  • Signatera - Multiple Myeloma - Product Description
  • Signatera - Multiple Myeloma - Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
  • Signatera - Non-Hodgkin's Lymphoma - Product Status
  • Signatera - Non-Hodgkin's Lymphoma - Product Description
  • Signatera - Pan-Cancer - Product Status
  • Signatera - Pan-Cancer - Product Description
  • Signatera - Prostate Cancer - Product Status
  • Signatera - Prostate Cancer - Product Description
  • Signatera Companion Diagnostic - Tecentriq - Product Status
  • Signatera Companion Diagnostic - Tecentriq - Product Description
Natera Inc, Key Employees
  • Natera Inc, Other Locations
  • Natera Inc, Subsidiaries
  • Glossary
List of Figures
  • Natera Inc Pipeline Products by Equipment Type
  • Natera Inc Pipeline Products by Development Stage
  • Natera Inc Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
  • Guardant Health Inc
  • Adaptive Biotechnologies Corp
  • Personal Genome Diagnostics Inc
  • Roche Diagnostics International Ltd
  • Exact Sciences Corp
Note: Product cover images may vary from those shown
Adroll
adroll